Spero Therapeutics, Inc.
No enriched coverage for $SPRO in the last 7 days.
No SEC Form 4 filings for $SPRO in the last 30 days.
See all $SPRO insider activity →Spero Therapeutics, Inc. (SPRO) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On August 28, 2026, Spero Therapeutics, Inc., a Delaware corporation (the “Company”), entered into an Open Market Sale Agreement℠ (the “Sale Agreement”) with Jefferies LLC, as agent (“Jefferies”), pursuant to which the Company
Intuit forecasted slower sales growth and shares fell 9.8% after-hours. Spyre Therapeutics abandoned a drug candidate after trial results missed targets, dropping 11%. Zoom Communications' Q3 EPS guidance missed estimates, shares down 3.9%. nCino's Q3 revenue projection fell short of expectations, stock down 5.6%.
Spero Therapeutics (SPRO) reported Q2 2026 earnings: $0 revenue, $9.6M net loss, $0.16 loss per share. R&D expenses fell to $3.4M, while G&A rose to $6.5M. The company secured $105M in royalty financing from Healthcare Royalty, backed by GSK's Utebzi payments. SPRO plans to advance SP001, licensed from Innovent, for IgG4-related disease, with a Phase II trial expected in Q2 2027. Management expects current capital to fund operations into 2H 2029. Utebzi, approved by the FDA, is anticipated to la
Recent SPRO coverage spans corporate actions, earnings and mergers & acquisitions.
Potential dilution and cash infusion of up to $100 M; shares may be sold incrementally, affecting supply and price.
Trial setback reduces near‑term upside.
Earnings miss and large financing indicate cash runway but highlight lack of revenue, potentially pressuring the stock.
Financing reduces near-term funding risk through 2H 2029, while SP001 licensing and planned Phase II timing shape longer-dated valuation expectations.
Multiple catalysts in one filing: FDA approval for Utebzi (via GSK), new Phase 2-ready SP001 program, and non-dilutive royalty financing to fund SP001 into 2029.
alphai scores every news story that mentions SPRO with an AI model for sentiment and relevance, and aggregates insider trades from Spero Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Spero Therapeutics, Inc. (SPRO) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On August 28, 2026, Spero Therapeutics, Inc., a Delaware corporation (the “Company”), entered into an Open Market Sale Agreement℠ (the “Sale Agreement”) with Jefferies LLC, as agent (“Jefferies”), pursuant to which the Company
2 min readIntuit forecasted slower sales growth and shares fell 9.8% after-hours. Spyre Therapeutics abandoned a drug candidate after trial results missed targets, dropping 11%. Zoom Communications' Q3 EPS guidance missed estimates, shares down 3.9%. nCino's Q3 revenue projection fell short of expectations, stock down 5.6%.
2 min readSpero Therapeutics (SPRO) reported Q2 2026 earnings: $0 revenue, $9.6M net loss, $0.16 loss per share. R&D expenses fell to $3.4M, while G&A rose to $6.5M. The company secured $105M in royalty financing from Healthcare Royalty, backed by GSK's Utebzi payments. SPRO plans to advance SP001, licensed from Innovent, for IgG4-related disease, with a Phase II trial expected in Q2 2027. Management expects current capital to fund operations into 2H 2029. Utebzi, approved by the FDA, is anticipated to la
2 min readSpero Therapeutics (NASDAQ:SPRO) reported Q2 2026 revenue of $0 versus $14.2M in Q2 2025, with R&D expense down to $3.4M and G&A up to $6.5M. Net loss was $9.6M. Spero also closed a $105M royalty financing tied to GSK’s Utebzi milestones/royalties, and licensed SP001 (IBI355) from Innovent with $1.1B contingent value; SP001 Phase II in IgG4-RD is expected to start Q2 2027.
6 min readSpero Therapeutics, Inc. (SPRO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Spero Therapeutics Announces Second Quarter 2026 Operating Results and Provides Business Update • Entered an exclusive license agreement with Innovent Biologics for SP001, a Phase 2-ready, third-generation anti-CD40L antibody for immune-mediated diseases • U.S. Food
6 min readInnovent Biologics licensed IBI355, an Fc-silent anti-CD40L antibody, to Spero Therapeutics for up to $1.1bn. Spero will run a global Phase II study starting Q2 2027, while Innovent keeps commercial rights in Mainland China, Hong Kong, Macau and Taiwan. Innovent also plans a China Phase II for Sjögren’s by early 2027, with upfront, milestones and royalties.
4 min readInnovent Biologics said it signed an exclusive licensing deal with Spero Therapeutics for IBI355, an anti-CD40L antibody for autoimmune diseases. Innovent will get an upfront payment plus development, regulatory and commercial milestones totaling up to about $1.1 billion, and tiered royalties. Spero gets worldwide rights excluding Greater China. IBI355 is in Phase 1 and Phase 2 plans.
2 min readSpero Therapeutics (Nasdaq: SPRO) announced a $105 million non-recourse, non-dilutive royalty financing with affiliates of Healthcare Royalty (KKR, HCRx). It funds Phase 2 development of SP001 using a portion of future Utebzi (tebipenem pivoxil) milestones and royalties from GSK. Spero updated cash runway to the second half of 2029.
4 min readSpero Therapeutics, Inc. (SPRO) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. 8-K false 0001701108 0001701108 2026-07-08 2026-07-08 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 8, 2
6 min readSpero Therapeutics shares fell about 12% premarket after it announced a $105M licensing deal with HCRx, an affiliate of Healthcare Royalty (KKR). HCRx will receive a share of future milestone and royalty payments tied to Utebzi (tebipenem pivoxil) sales, while Spero plans to fund SP001 Phase 2 and extend cash runway into 2H 2029.
3 min read
